YC Demo Day marked the beginning of Spring and a new chapter of growth for PLab. For two years (2014 and 2015) we operated not just as a lean startup, but as an ultra-lean startup — you could call it budgetary caloric restriction. Read more about how we made the transition, and the role YC played:
The 7th full-time PLab team member, Feba Sam, joined us last month. With Feba coming on board, PLab’s core team of scientists is now majority women. She wasted no time getting assays to work:
Today was the first day of our new cell culture Research Associate, Feba Sam! She'll be working with @NinaDiPrimio.
— Perlara (@PerlaraPBC) May 2, 2016
— Nina DiPrimio (@NinaDiPrimio) May 13, 2016
— Nina DiPrimio (@NinaDiPrimio) May 20, 2016
Tom’s and Tamy’s painstaking efforts over the last 5 months to upgrade PLab’s platform capabilities for fly screens started to pay off. They worked closely with Peter Sands, founder of Modular Science, built a custom fly imaging rig. The plate images below are the fruits of their labor:
— Perlara (@PerlaraPBC) May 5, 2016
NGLY1 fly screen update: which rows contain heterozygotes vs homozygotes? pic.twitter.com/SUiL5pGwwX
— Perlara (@PerlaraPBC) May 19, 2016
Nina took to the blog to summarize recent data on the role of autophagy in Niemann-Pick C. This post was written in anticipation of the Ara Parseghian Medical Research Foundation’s 22nd annual meeting in Tucson, which I attended (and dutifully livetweeted; more on that in next month’s LMiT):
— Perlara (@PerlaraPBC) May 17, 2016
Parseghian Foundation's annual scientific conference on Niemann-Pick C is in 2 weeks in Tucson. @eperlste will present latest on PERL101.
— Perlara (@PerlaraPBC) May 23, 2016
My friend and unflagging rare disease advocate Oli Rayner brought to my attention a very interesting paper on a yeast model of cystic fibrosis. What makes this paper special is that is demonstrated the evolutionary conservation of a genetic modifier from yeast to human cells, specifically bronchial epithelial cells:
A yeast model of cystic fibrosis reveals an evolutionarily conserved suppressor of the most common CF mutation ΔF508 https://t.co/hV6POvMJGE
— Perlara (@PerlaraPBC) May 26, 2016
— Frank David • Pharmagellan (@Frank_S_David) May 30, 2016
Really interesting and important post by my friends @PerlsteinLab on how a yeast model can help CF drug discovery: https://t.co/60w8BBQqsf
— Oli Rayner (@oli_rayner) May 31, 2016
— Andrew G. (@BioDueDiligence) May 31, 2016
See you next month!